Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- Clayton girl named Children’s Miracle Network Championon January 27, 2021 at 1:37 pm
A young girl from Clayton, nicknamed “Natalie the Brave,” has been awarded the honor of being the local Children’s Miracle Network Champion.
- Kim Seon Ho Donates 100 Million Won To Korea Childhood Leukemia Foundationon January 27, 2021 at 9:46 am
Kim Seon Ho has made a large donation to the Korea Childhood Leukemia Foundation. On January 27, his agency SALT Entertainment confirmed with Sports Kyunghyang that he has donated 100 million won ...
- Newport native begins fight for 1-year-old daughter diagnosed with rare form of leukemiaon January 27, 2021 at 8:02 am
Only a dozen known cases of this subtype of leukemia have been identified and a bone marrow transplant is needed.
- Two Anti-viral Enzymes Transform Pre-Leukemia Stem Cells into Leukemiaon January 26, 2021 at 11:58 am
COVID-19 updates, including vaccine information, for our patients and visitors Learn More Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many ...
- Second child in family diagnosed with leukemiaon January 25, 2021 at 10:35 pm
Adley Ward, 3, has been diagnosed with leukemia, according a social media post by the family ... Tenley most recently has been at Cincinnati Children’s Hospital for treatment and therapy and was ...
- Acute Lymphoblastic Leukemia Market Trends 2020 | Segmentation, Outlook, Industry Report to 2026on January 23, 2021 at 12:12 am
Jan (Heraldkeepers) -- The global acute lymphoblastic leukemia market is growing at a significant CAGR during the forecast period. One of the ...
- ALL Survival Gap Persists Between Black, White Childrenon January 22, 2021 at 2:57 pm
Despite outcome improvements for acute lymphoblastic leukemia (ALL), mortality rates remain high, with significant survival disparities seen between Black and White children.
- Creating a safe CAR T-Cell therapy to fight solid tumors in childrenon January 22, 2021 at 1:18 am
CAR T—has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma. Preclinical studies using ...
- Henderson teen stays positive amid Leukemia diagnosison January 21, 2021 at 1:51 pm
It's been a week since Henderson teen, Addison Graham, was diagnosed with Leukemia, and the family is preparing for at least two years of treatments. The 14-year old will have to finish the school ...
- Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemiaon January 20, 2021 at 4:00 pm
Yang and colleagues perform a network system–pharmacology approach and clinical data integration, and identify LCK and BCL2 signaling as the molecular determinants of dasatinib response in pediatric ...
via Bing News